Drugs & Therapy Perspectives

, Volume 23, Issue 5, pp 7–11 | Cite as

Migraine management in elderly and paediatric patients is difficult, but can usually be managed effectively

Disease Management
  • 32 Downloads

References

  1. 1.
    Hämäläinen ML. Migraine in children and adolescents: a guide to drug treatment. CNS Drugs 2006; 20(10): 813–20PubMedCrossRefGoogle Scholar
  2. 2.
    Sarchielli P, Mancini ML, Calabresi P. Practical considerations for the treatment of elderly patients with migraine. Drugs Aging 2006; 23(6): 461–89PubMedCrossRefGoogle Scholar
  3. 3.
    Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005; 17(8): 309–17PubMedCrossRefGoogle Scholar
  4. 4.
    Deleu D, Hanssens Y, Worthing EA. Symptomatic and prophylactic treatment of migraine: a critical reappraisal. Clin Neuropharmacol 1998; 21(5): 267–79PubMedGoogle Scholar
  5. 5.
    Lewis D, Ashwal S, Hershey A, et al. American Academy of Neurology Quality Standards Subcommittee. Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004; 63: 2215–24PubMedCrossRefGoogle Scholar
  6. 6.
    Damen L, Bruijn JKJ, Verhagen AP, et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 2005; 116: 295–302CrossRefGoogle Scholar
  7. 7.
    Winner P, Rothner AD, Saper J, et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics 2000; 106(5): 989–97PubMedCrossRefGoogle Scholar
  8. 8.
    Winner P, Rothner AD, Wooten JD, et al. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache 2006; 46: 212–22PubMedCrossRefGoogle Scholar
  9. 9.
    Kabbouche MA, Vockell AL, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics 2001; 107(4): E62PubMedCrossRefGoogle Scholar
  10. 10.
    Brousseau DC, Duffy SJ, Anderson AC, et al. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004; 43: 256–62PubMedCrossRefGoogle Scholar
  11. 11.
    Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12(2): 133–41PubMedCrossRefGoogle Scholar
  12. 12.
    Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Triptan Cardiovascular Safety Expert Panel. Headache 2004; 44(5): 414–25PubMedCrossRefGoogle Scholar
  13. 13.
    Adelman JU, Lewit EJ. Comparative aspects of triptans in treating migraine. Clin Cornerstone 2001; 4(3): 53–64PubMedCrossRefGoogle Scholar
  14. 14.
    Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62(4): 563–8PubMedCrossRefGoogle Scholar
  15. 15.
    Diener HC, Limmroth V. Analgesics. Curr Med Res Opin 2001; 17Suppl. 1: 13S–6SCrossRefGoogle Scholar
  16. 16.
    Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs 2004; 64(22): 2503–14PubMedCrossRefGoogle Scholar
  17. 17.
    Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 2005; 19(9): 769–84PubMedCrossRefGoogle Scholar
  18. 18.
    Gladstone JP, Eross EJ, Dodick DW. Migraine in special populations: treatment strategies for children and adolescents, pregnant women, and the elderly. Postgrad Med 2004; 115(4): 39–44, 47-50PubMedCrossRefGoogle Scholar
  19. 19.
    Ashkenazi A. Silberstein SD. Hormone-related headache: pathophysiology and treatment. CNS Drugs 2006; 20(2): 125–41PubMedCrossRefGoogle Scholar
  20. 20.
    Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225Google Scholar
  21. 21.
    Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 1997; 156(9): 1273–87PubMedGoogle Scholar
  22. 22.
    Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7(1): 51–4PubMedCrossRefGoogle Scholar
  23. 23.
    Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45(2): 144–52PubMedCrossRefGoogle Scholar
  24. 24.
    Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107(1): 44–8PubMedCrossRefGoogle Scholar
  25. 25.
    Moja P, Cusi C, Sterzi R, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919Google Scholar
  26. 26.
    Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39(1): 28–32PubMedCrossRefGoogle Scholar
  27. 27.
    Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47(1): 34–57PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Personalised recommendations